Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Fluticasone Furoate/Vilanterol vs Fluticasone Furoate in Japanese Asthma Patients
NCT01244984Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2010
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vilanterol in asthma (2 arms), sponsored by GSK. Primary endpoint: Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) at 52 weeks. Started Jul 2010; status: completed.
02
Drugs
vilanterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01244984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01244984.